Xilio gets a Gilead-shaped reprieve
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
